SURMOUNT-2 Trial: Tirzepatide Delivers 15.7% Weight Loss in Adults With Obesity and Diabetes

Medically reviewed by Dr. James Whitfield, DO, FACOI

The SURMOUNT-2 trial, published in The Lancet in 2023 by Garvey et al., tackled one of obesity medicine's greatest challenges: achieving significant weight loss in patients who have both obesity and type 2 diabetes. Tirzepatide 15mg delivered 15.7% weight loss over 72 weeks in this dual-diagnosis population — results that were previously considered unattainable without surgery.

SURMOUNT-2: Cracking the Obesity-Diabetes Code

Patients with both obesity and type 2 diabetes represent one of the most challenging populations in weight management. Diabetes medications often promote weight gain, insulin resistance makes fat loss harder, and the metabolic dysfunction of diabetes blunts the weight-lowering effects of most anti-obesity drugs. The SURMOUNT-2 trial, published in The Lancet in August 2023 by Garvey et al., demonstrated that tirzepatide could overcome these barriers [1].

The Challenge of Diabetic Obesity

Historically, patients with type 2 diabetes lose significantly less weight with anti-obesity medications compared to non-diabetic patients:

In the STEP 2 trial, semaglutide 2.4 mg produced 9.6% weight loss in diabetic patients vs. 14.9% in STEP 1 (non-diabetic)

This "diabetes penalty" of approximately 30-40% less weight loss has been consistent across multiple drug classes

The reasons include insulin resistance, compensatory hyperinsulinemia, and the weight-promoting effects of improved glycemic control

SURMOUNT-2 was specifically designed to test whether tirzepatide's dual mechanism could overcome this diabetes penalty [1].

---

> Want personalized dosing and protocol guidance? The providers at Telegenix specialize in peptide therapy and TRT, designing protocols around your unique labs and health objectives. Get started with a free consultation.

---

Study Design

SURMOUNT-2 enrolled 938 adults with both obesity (BMI ≥27 with weight-related comorbidity, or BMI ≥30) and type 2 diabetes across 77 sites in 7 countries.

Key Design Features:

72-week, double-blind, randomized, placebo-controlled

Randomized 1:1:1 to tirzepatide 10 mg, 15 mg, or placebo

Background metformin allowed (most patients were on it)

Standard lifestyle intervention counseling

Baseline HbA1c: approximately 8.0%

Baseline weight: approximately 100 kg

Weight Loss Results

Tirzepatide produced remarkable weight loss despite the diabetic population:

Mean Body Weight Change at 72 Weeks:

Tirzepatide 10 mg: -12.8% (approximately -13.5 kg)

Tirzepatide 15 mg: -14.7% (approximately -15.6 kg)

Placebo: -3.2% (approximately -3.4 kg)

Using the efficacy estimand (on-treatment analysis):

Tirzepatide 15 mg: -15.7%

Categorical Weight Loss:

≥5% weight loss: 79% (10 mg), 83% (15 mg) vs. 32% (placebo)

≥10% weight loss: 57% (10 mg), 65% (15 mg) vs. 10% (placebo)

≥15% weight loss: 36% (10 mg), 48% (15 mg) vs. 3% (placebo)

≥20% weight loss: 20% (10 mg), 30% (15 mg) vs. 1% (placebo)

Overcoming the Diabetes Penalty

Comparing SURMOUNT-2 to SURMOUNT-1 reveals how tirzepatide handles the diabetes penalty:

|---|---|---|---|

| SURMOUNT-1 | No diabetes | 22.5% | — |

| STEP 1 (semaglutide) | No diabetes | 14.9% | — |

While tirzepatide also shows a diabetes penalty, the absolute weight loss in the diabetic population (14.7%) is comparable to what semaglutide achieves in non-diabetic patients (14.9%). This means tirzepatide in diabetic patients produces results similar to semaglutide in its best-case scenario [1].

Glycemic Control

As expected, the glycemic improvements were substantial:

HbA1c reduction: -2.1% (10 mg), -2.4% (15 mg) vs. -0.5% (placebo)

HbA1c <7.0%: 81% (10 mg), 86% (15 mg) vs. 24% (placebo)

HbA1c <5.7%: 28% (10 mg), 44% (15 mg) vs. 2% (placebo)

Many patients were able to reduce or eliminate their diabetes medications during the trial, suggesting that the combination of weight loss and direct glucose-lowering effects could achieve diabetes remission in a significant proportion of patients [1].

Safety Profile

The safety data were consistent with previous tirzepatide trials:

Nausea: 18-24% vs. 4% (placebo)

Diarrhea: 18-21% vs. 9%

Vomiting: 8-11% vs. 2%

Hypoglycemia (<54 mg/dL): 0.6-1.3% vs. 0% (low risk without sulfonylureas)

Discontinuation due to AEs: 3-6% vs. 1%

Clinical Implications

SURMOUNT-2 has several important implications for clinical practice:

Dual benefit: Tirzepatide simultaneously addresses both obesity and diabetes, simplifying treatment

Medication reduction: Many patients can reduce or stop other diabetes medications

Cost-effectiveness: Treating two conditions with one drug may improve cost-effectiveness

Treatment sequencing: Supports early use of tirzepatide in patients with both conditions rather than treating each separately

> Related Comparison: MOTS-C vs Metformin: Metabolic Comparison

> Related Comparison: Ozempic vs Mounjaro: Complete Comparison

References

Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." The Lancet. 2023;402(10402):613-626. PubMed: 37385275

Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. PubMed: 35658024

Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. PubMed: 33567185

---

> Take the next step in your optimization journey. If you're ready to move beyond research and into a supervised protocol, Telegenix offers physician-guided peptide and TRT programs with full lab support. Book a free consultation today.

---